Beta
370774

Assessment of Interleukin-22 mRNA as a Diagnostic Marker for Polycystic Ovary Syndrome -Associated Metabolic Dysfunction

Article

Last updated: 01 Jan 2025

Subjects

-

Tags

Internal Medicine

Abstract

Abstract

Background: Metabolic abnormalities and immune dysregulations are the most common risk factors for polycystic ovary syndrome (PCOS). Interleukin-22 (IL-22) is implicated in the pathogenesis of the immune-inflammatory system in the context of metabolic dysfunction. In the current research, we aimed to investigate IL-22 mRNA in PCOS and explore its correlations with metabolic syndrome (MetS) and reproductive features of PCOS.

Methods: we conducted our research on 60 women as control groups, and 70 patients with PCOS (30 patients without MetS and 40 patients with MetS). We investigated serum IL-22 by ELISA. At the same time, the IL-22 mRNA level was analyzed by RT-qPCR.

Results: Among 70 women with PCOS, 40 (57.1%) had metabolic syndrome. women with PCOS had significantly lower serum and mRNA Expression Levels of IL-22 compared to control. Even more importantly, among PCOS patients, women with MetS had significantly lower serum and mRNA Expression levels of IL-22 compared to women without MetS. serum and mRNA Expression levels of IL-22 were negatively associated with MetS components and inflammatory markers as well as reproductive features of PCOS. The AUC of serum and mRNA levels of IL-22 in the prediction of MetS among PCOS women had a sensitivity of 90%, and 77.5%, respectively, and specificity of 66%, 87.3% and respectively.

Conclusion: PCOS patients had significantly serum and mRNA Expression levels of IL-22 than controls. the lowered IL-22 serum and mRNA levels could be used as diagnostic markers of PCOS patients more specifically women with MetS.

DOI

10.21608/zumj.2024.305018.3481

Keywords

Interleukin-22, inflammatory markers, polycystic ovary syndrome, Metabolic syndrome, reproductive phenotypes,

Authors

First Name

Nearmeen

Last Name

Rashad

MiddleName

-

Affiliation

Diabetes and Endocrine Unit -Internal Medicin Departement -Zagazig University

Email

nrashad78@yahoo.com

City

zagazig

Orcid

0000-0003-1746-3514

First Name

Yaser

Last Name

Saraya

MiddleName

Samir

Affiliation

Gynecology and Obstetrics, Faculty of Medicine, Zagazig University

Email

dryassersaraya314@gmail.com

City

-

Orcid

-

First Name

Eman

Last Name

Abdel Aziz

MiddleName

-

Affiliation

clinical pathology department, faculty of medicine, Zagazig university

Email

m_farouk82@yahoo.com

City

-

Orcid

-

First Name

Amira

Last Name

Gobran

MiddleName

Mokhtar

Affiliation

phsiology department . faculty of medicine zagazig university

Email

drmero.gobran@gmail.com

City

zagazig

Orcid

0000-0003-2680-6195

First Name

Rehab

Last Name

Atef

MiddleName

-

Affiliation

Medical Biochemistry Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt Biochemistry Department, College of Medicine, Taif University, Taif, Saudi Arabia

Email

rehabshaabab2014@gmail.com

City

-

Orcid

-

First Name

Azza

Last Name

Abd El-Fatah

MiddleName

Hassan

Affiliation

Lecturer of Internal Medicine, Faculty of Medicine, Zagazig University

Email

azza.hassan4578@gmail.com

City

-

Orcid

-

First Name

mayada

Last Name

mousa

MiddleName

-

Affiliation

zagazig university

Email

mayadamousa1979@gmail.com

City

-

Orcid

-

Volume

30

Article Issue

1.5

Related Issue

49735

Issue Date

2024-08-01

Receive Date

2024-07-22

Publish Date

2024-08-01

Page Start

2,059

Page End

2,066

Print ISSN

1110-1431

Online ISSN

2357-0717

Link

https://zumj.journals.ekb.eg/article_370774.html

Detail API

https://zumj.journals.ekb.eg/service?article_code=370774

Order

12

Type

Original Article

Type Code

273

Publication Type

Journal

Publication Title

Zagazig University Medical Journal

Publication Link

https://zumj.journals.ekb.eg/

MainTitle

Assessment of Interleukin-22 mRNA as a Diagnostic Marker for Polycystic Ovary Syndrome -Associated Metabolic Dysfunction

Details

Type

Article

Created At

30 Dec 2024